By Editorial TeamThe massive burden of cardiovascular disease is one of healthcare’s biggest problems, and that makes it one of the most interesting places to invest. For VCs looking at the health AI space, the main job is telling the difference between a company that can actually scale and a science project that just burns cash. Our analysis of which companies survive and which don’t shows one thing over and over: capital follows scalability. In health AI, scalability comes from two things: proof that you’re improving clinical outcomes and a clear path to getting payers to write you checks.
The Data-Driven Divide: Viz.ai’s Traction vs. Olive AI’s Cautionary Tale
When you’re trying to figure out which AI cardiology platforms are set for real growth, you have to look past the splashy funding announcements. You need to dig into the business model to see if it can actually penetrate the market. The difference between a company like Viz.ai and the now-defunct Olive AI tells the whole story. Viz.ai shows what happens when you build a business on clinical utility and have a smart regulatory plan. By focusing on improving acute care for things like stroke and vascular disease, they’ve delivered real, tangible results for hospitals. The company’s $100 million Series D round, which put its valuation at $1.2 billion, wasn’t just speculative money from firms like Tiger Global. It was a bet on Viz.ai’s proven ability to make clinics more efficient and improve patient outcomes which is the only way you build a foundation for long-term payer contracts. Their product, a Software as a Medical Device (SaMD), uses AI to help doctors make critical decisions faster, acting as a perfect “wedge product” that fits right into how hospitals already work. On the other hand, look at Olive AI. They raised something like $900 million, also with significant money from Tiger Global, and still ended up shutting down completely. Olive had a big vision to automate all sorts of administrative tasks in healthcare, which sounded great. The problem was they could never consistently show a measurable ROI for their customers. Without clear, repeatable outcomes (clinical or operational), and facing the huge complexity of trying to stitch together different AI tools across giant hospital systems, their business became a case study in capital inefficiency and an unsustainable burn rate. The lesson is painful but simple: no amount of capital can save a company that can’t prove its value with a scalable model that fits how healthcare actually works.
Clinical Validation and Payer Contracts: The Bedrock of Durability
Our proprietary funding database proves it: companies that have published clinical data and already have payer contracts lined up have far more staying power. This is a quantifiable pattern. For any cardiovascular AI platform, this means proving the AI actually makes a difference in patient care, cuts costs, or boosts efficiency in a way that makes payers willing to open their wallets. Take the development path of a clinical-stage digital therapeutic for cardiovascular health, like some of the work being done at Tempus AI. While most people know Tempus AI for their cancer-focused precision medicine, their bigger plan involves using their massive datasets across many areas, including cardiology. The fact that GV invested in Tempus AI, helping it reach a market cap of around $12.8 billion as of August 2026, shows a deep confidence in their data moat. Investors are betting on their ability to turn genomic and clinical data into real insights and, eventually, products that get reimbursed. For a cardiology AI company, having a huge, proprietary data moat, built on millions of labeled ECGs or imaging studies, is a massive competitive advantage that makes it almost impossible for newcomers to compete on accuracy. Getting long-term funding in cardiovascular AI means ticking a bunch of very specific boxes: you need regulatory clearance like a 510(k) or De Novo for your SaMD, you need strong Real-World Evidence (RWE) to prove your tech works, and you absolutely must get CPT codes, both Category I and III, so you can actually get reimbursed. During technical due diligence, investors look for signs of maturity and regulatory savvy, so showing you’re compliant with GMLP (Good Machine Learning Practice) and have a solid QMS (Quality Management System) based on standards like ISO 13485 is a huge plus.
Investor Checklist for Evaluating Clinical Scalability in Cardiovascular AI
To invest in the high-stakes field of cardiovascular AI, you need a tough due diligence checklist that focuses on what’s really scalable. Here’s what we recommend:
- Clinical Evidence: Does the company have studies in peer-reviewed journals showing clear clinical outcomes? Is there solid Real-World Evidence (RWE) backing up its performance in different kinds of patients? Example of a peer-reviewed study on AI for cardiovascular risk prediction Focus on verifiable impact, not speculative potential.
- Regulatory Pathway Clarity: Has the company already gotten an FDA 510(k) clearance or De Novo classification? What’s the plan for dealing with Algorithmic Drift, do they have a Predetermined Change Control Plan (PCCP) in place? Having regulatory certainty makes the whole investment much less risky.
- Reimbursement Strategy: Are there existing CPT codes they can use, or do they have a believable plan to get new ones? Have they landed any early payer contracts or at least gotten strong interest from major insurers? For inpatient tech, getting an NTAP (New Technology Add-On Payment) is a very strong positive signal.
- Data Moat & AI-Native Architecture: Does the company have a proprietary dataset that’s hard for anyone else to build? Was the entire company, the product, the data pipeline, the business model, built around AI from day one (is it an “AI-Native Company”)?
- Technical & Security Maturity: Can they prove they adhere to HIPAA, HITRUST, or SOC 2 standards? If a company doesn’t have these security and privacy certifications, it’s an immediate red flag during diligence. Explanation of SOC 2 compliance for healthcare startups
- Market Penetration Model: Is the product a smart, focused “wedge product” that can get a foothold in the market before they try to expand? Or is it some huge, expensive, and overly ambitious platform with no clear ROI?
- Avoid Zombie Companies: Watch out for companies that raised some early money but now have no clear path to their next round or sustainable growth. A big sign of a zombie is a product that has regulatory clearance but nobody is actually using it.
Methodology Note
Our analysis is built on a complete database of healthcare AI funding that we update constantly. We track everything: round sizes, who the investors are, valuation milestones, and we run detailed analyses on which companies last. Our conclusions are pulled from quantitative data, public financial filings, verified funding press releases, and academic papers on clinical results. This “Market Signal Analysis” uses an “Expert Synthesis” of “Analysis of Public Financial Data” to give investors an objective view based on hard numbers. By focusing on what the data says, we can cut through the hype and find the real, scalable opportunities in the cardiovascular AI field. Overview of the AI Health Investment Tracker’s data collection methodology
Frequently Asked Questions
What distinguishes scalable healthcare AI companies from those that struggle to achieve sustainable growth?
Scalable healthcare AI companies demonstrate clear clinical outcomes and have established payer pathways. They focus on delivering measurable ROI for customers and integrate seamlessly into existing clinical workflows, as exemplified by Viz.ai’s success in acute care pathways. Companies lacking this demonstrable value, like Olive AI, struggle with capital inefficiency and unsustainable burn rates despite significant funding.
What are the key indicators of ‘funding durability’ in cardiovascular AI investments?
Funding durability is strongly linked to published clinical outcomes and established payer contracts. Companies that can show their AI meaningfully impacts patient care, reduces costs, or improves efficiency in ways payers are willing to reimburse exhibit more durable funding trajectories. Regulatory clearances, strong Real-World Evidence, and attainment of CPT codes are also critical indicators.
How important are regulatory clearances and a clear reimbursement strategy for cardiovascular AI platforms?
Regulatory clearances (like FDA 510(k) or De Novo) and a clear reimbursement strategy are foundational for durable funding. These ensure the product can be legally marketed and that there’s a pathway for healthcare providers to get paid for using it. Companies demonstrating GMLP compliance and a robust QMS further signal maturity and regulatory preparedness, de-risking the investment.
What is a ‘data moat’ and why is it important for cardiovascular AI companies?
A ‘data moat’ refers to a proprietary and extensive dataset that is difficult for competitors to replicate. For cardiovascular AI platforms, this could involve millions of labeled ECG recordings or imaging studies. Such a moat provides a critical competitive advantage by enabling superior accuracy and performance, making it challenging for new entrants to match the company’s capabilities.
